III: IVERMECTIN
- Ivermectin is considered a “Wonder drug” alongside penicillin and aspirin due to its significant positive impact on global health.
- It is recognized for its versatility, safety, and ongoing benefits, particularly for impoverished populations.
- Three statues at the Carter Center, World Bank, and World Health Organization commemorate the development of ivermectin.
- Since 2012, in-vitro studies reveal that ivermectin (IVM) inhibits various viruses.
- A 2020 Nature Magazine study reviewed 50 years of research and identified IVM as “highly effective against microorganisms,” demonstrating antiviral effects against viruses like Zika and dengue.
- An Australian study on April 3, 2020, reported that IVM eliminated SARS-CoV-2 in cell cultures within 48 hours, gaining global attention for its potential as a COVID treatment.
- Peru adopted IVM in its national guidelines on May 8, 2020, leading to a significant decrease in COVID deaths, correlated with IVM distribution.
- After restrictions imposed in December 2020, COVID cases and deaths surged again in Peru.
- IVM showed greater efficacy against COVID than vaccines at a lower cost; a study in Argentina recorded 100% efficacy as a preventative measure among workers.
- An observational study in Bangladesh found minimal cases of COVID-19 symptoms among healthcare workers who used IVM prophylactically compared to controls who did not.
- A 2021 study indicates ivermectin (IVM) competitively binds with the SARS-CoV-2 spike protein, suggesting effectiveness against all variants, unlike vaccines.
- Initial utilization of IVM began in March 2020 by ICU and ER doctors, showing increased recovery rates; Dr. Jean-Jacques Rajter noted an uptick in patients’ recoveries.
- More than 20 randomized clinical trials (RCTs) since March 2020 confirm IVM’s efficacy for both inpatient and outpatient COVID-19 treatment, with six of seven meta-analyses in 2021 showing reduced mortality.
- Dr. Harvey Risch noted significant benefits for high-risk outpatients; late-stage patients also showed some benefits.
- A 2020 review emphasized numerous clinical studies displaying substantial efficacy of IVM in prophylaxis and treatment of COVID-19.
- Dr. David Chesler recorded an 8% mortality rate using IVM in nursing homes, considerably lower than the US average; he sought acknowledgment from Dr. Fauci.
- A French nursing home reported zero severe cases among residents who had taken IVM for scabies.
- Research suggests IVM may work via various mechanisms, including facilitating zinc transfer, blocking viral replication, and reducing inflammation.
- IVM impedes the spike protein’s attachment to ACE2 receptors, preventing viral entry, while also preventing blood clots related to spike protein interactions.
- IVM’s preventive role can halt infection and transmission within communities.
Recent Comments